

Edgar Filing: NEUROLOGIX INC/DE - Form 8-K

NEUROLOGIX INC/DE
Form 8-K
October 06, 2005

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 2, 2005

Neurologix, Inc.
(Exact name of registrant as specified in its charter)

DELAWARE	0-13347	06-1582875
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	I.R.S. Employer Identification No.)
ONE BRIDGE PLAZA, FORT LEE, NEW JERSEY		07024
(Address of principal executive offices)		(Zip Code)

(201) 592-6451

(Registrant's telephone number,
including area code)

None

(Former name, former address and former fiscal year,
if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13(e)-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective October 1, 2005, Mark S. Hoffman resigned as a member of the Board of Directors (the "Board") of Neurologix, Inc. (the "Company") and also resigned as the Secretary and Treasurer of the Company.

Edgar Filing: NEUROLOGIX INC/DE - Form 8-K

Mr. Hoffman's resignation is part of a realignment of responsibilities for the private equity portfolio holdings of Palisade Capital Management, a private investment firm and affiliate of Palisade Private Partnership L.P., which owns approximately 26% of the Company's shares.

The Board appreciates Mr. Hoffman's service to the Company. The Board expects to appoint a new director to fill the vacancy created by Mr. Hoffman's resignation as soon as practicable. The Company is also seeking to hire a new officer to replace Mr. Hoffman as Secretary and Treasurer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 6, 2005

NEUROLOGIX, INC.

By: /s/ Michael Sorell

Name: Michael Sorell, M.D.
Title: President and
Chief Executive Officer